The drug is indicated for the treatment of schizophrenia and for additional maintenance treatment of bipolar disorder.

The Food and Drug Administration has approved the use of the powerful antipsychotic drug Risperdal for use in preteens and teenagers with schizophrenia or manic depressive illness. Risperdal can be ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that four studies across its ...

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...

Amneal has received the Food and Drug Administration’s approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which is the generic of ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)-- Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell ...

March 24, 2010 — One year of maintenance risperidone administered at the initial therapeutic dose for acute schizophrenia is more effective at preventing relapse than dose reduction strategies and is ...

Patients. A total of 675 patients were involved in the ITT analysis (risperidone group, n = 349; conventional antipsychotic group, n = 326). The baseline demographics and the clinical characteristics ...

A major U.K. study of more than 165,000 dementia patients has found that risperidone raises stroke risk without exception, challenging safety assumptions by leaving no "safe group." Subscribe to our ...